Grant of Options and PDMR dealing

Feedback plc

Grant of Options and PDMR dealing

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces that it has granted a total of 254,117 options to subscribe for new ordinary shares of 1 penny each in the Company ("Ordinary Shares") under the Company's EMI Share Option Scheme (the "Options") to a person discharging managerial responsibilities (PDMR) and other employees, as detailed below.

The Options are being issued to appropriately incentivise and retain talent, as well as to ensure their interests are aligned with that of the Company and its Shareholders. The Options are exercisable at a price of 20 pence per share, reflecting the price at which the Company last completed an equity fundraise in November 2024 and representing a premium of 37.9 per cent to the closing share price on the last trading day before this announcement.

219,073 Options are being granted to a PDMR as set out below. The Options will vest in four equal tranches as follows:

· 25% vest in three equal sub-tranches annually (8.33% on each of the first, second and third anniversary of grant of 10 July 2025)

· 25% vest on reported revenue of £8m

· 25% vest on reported revenue of £12m; and

· 25% vest on reported revenue of £20m

"Reported Revenue" is either:

· a year's revenue reported in the full year audited financial statements; or

· 12 months' revenue being H2 of the last full year audited financial statements plus H1 of the last published interim financial statements.

Options being granted to the PDMR which are subject to the vesting conditions above:

* Employed by Feedback Medical Limited, a 100% subsidiary of Feedback plc

In addition, 35,044 Options were awarded to four employees on 10 July 2025 with the same exercise price and vesting conditions as the PDMR as set out above.

The Options are exercisable for a period of 5 years from the vesting date.

The Options represent in aggregate 0.6% of the Company's existing issued share capital.

Following the grant of the Options and taking into account existing options, the Company has a total of 4,042,913 options to subscribe for ordinary shares in the Company in issue, representing 9.2% of the Company's issued share capital at the date of this announcement.

The FCA notifications, made in accordance with the requirements of the EU Market Abuse Regulation, are appended below.

Further information on Feedback and its products can be found on the Company's website: https://feedbackmedical.com

-Ends-

Enquiries:

About Feedback plc

Feedback plc liberates the data and knowledge from multiple healthcare IT systems and delivers better workflow to enable clinicians to communicate, collaborate and provide the best healthcare for their patients. We connect care settings with diagnostic and other relevant data to drive better, faster, safer decision that improve outcomes for patients.

By linking different clinical systems together into a seamless view of the patient, we can streamline patient pathways and deliver a digital health and diagnostics record across multiple care providers.

Bleepa® is our communication and collaboration platform that displays clinical results at a certified and regulated quality, which enables multi-disciplinary team working and diagnostic-enhanced advice and guidance. CareLocker® is our patient-facing platform that gives patients access and control over their diagnostic and other clinical data.

The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

https://fbk.com

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities under UK MAR